Provexis Regulatory News (PXS)

12 February 2010

Provexis plc

("Provexis" or the "Company")

Director Shareholdings and Additional Listing

The Company has been informed that on 12 February 2010, Stephen Moon, a director of the Company, sold 6,000,000 ordinary shares of 0.1 pence each in the Company ("Ordinary Share") at a price of 7.2 pence per Ordinary Share.

Following this sale, Stephen Moon has a total beneficial and non-beneficial holding of 1,540,000 Ordinary Shares in the Company, representing 0.14 per cent of the current issued share capital of the Company.

Stephen Moon retains the same beneficial interest in 21,117,620 share options in the Company, representing 1.9 per cent of the current issued share capital of the Company.

The Company also announces that application has been made for the admission to AIM of 330,300 Ordinary Shares ("New Ordinary Shares"), pursuant to the exercise of options by Dr Neville Bain, a non-executive director of the Company, at an exercise price of 1.0p per share. Dr Bain received the 330,300 share options prior to the Group joining AIM, and he sold the Ordinary Shares issued as a result of the exercise of these options at a price of 7.08 pence per Ordinary Share.

Following the exercise, Dr Bain has no further options over Ordinary Shares, and he retains the same beneficial interest in 5,608,416 shares in the Company, representing 0.5% of the enlarged issued share capital of the Company.

The New Ordinary Shares will when issued rank pari passu with the Company's existing issued Ordinary Shares, and dealings are expected to commence on 19 February 2010 ("Admission").

Following Admission, the Company's enlarged issued share capital will comprise 1,108,081,929 Ordinary Shares with voting rights. The Company does not hold any shares in treasury. This figure of 1,108,081,929 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules.

For further information please contact: